acf/google-ad-placement

<ul>
	<li>Credit Suisse&nbsp;downgraded&nbsp;Immunovant Inc&nbsp;IMVT&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/quote/IMVT/analyst-ratings" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">to Underperform from Neutral</a>&nbsp;and lowered the price target to $7 from $12.&nbsp;</li>
	<li>Analyst&nbsp;Tiago Fauth&nbsp;says that the downgrade reflects ongoing clinical and regulatory uncertainties for IMVT-1401 owing to safety concerns, likely extended clinical timelines with no clear value-driving catalysts in the next 12-months.</li>
	<li>According to the analyst, the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/08/22272764/immunovant-stock-plunges-on-200m-equity-investment-from-roivant-to-support-imvt-1401-development" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">$200M equity investment</a>&nbsp;from&nbsp;Roivant Sciences&nbsp;has significantly reduced near-term M&amp;A expectations as well.</li>
	<li>In March, Roivant revealed in an SEC filing&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/03/20057497/why-immunovant-anchiano-opgen-are-rallying-today" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">to acquire all the shares in Immunovant</a>.</li>
	<li>Price Action:&nbsp;IMVT shares are down 23.5% at $8 during the market session on the last check Monday.</li>
</ul>

Analyst Color

Biotech

News

Short Ideas

Downgrades

Health Care

Price Target

Offerings

Small Cap

Analyst Ratings

Movers

Trading Ideas

General

Immunovant Stock Plunges After Credit Suisse Downgrade Citing Unclear Catalysts - Immunovant (NASDAQ:IMVT)